Jie Li

发表

Sorafenib improves the postoperative effect of early stage renal cell carcinoma

Z. Hui, Taiyang Liu, Jie Li, 2016, Oncology letters.

Real-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study

Jie Li, P. Zhao, Xuezhen Ma, 2021, Cancer management and research.

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

Andrew L. Kung, Matthew D. Wilkerson, Michael D. Cameron, 2012, Nature.

Experimental and clinical observations of 99mTc-MIBI uptake correlate with P-glycoprotein expression in lung cancer

Xianwen Meng, Xu Li, Jianjun Xue, 2007, Nuclear medicine communications.

PD‐L1 heterogeneity in patients with non–small cell lung cancer

X. Ye, Jie Li, Xia Yang, 2021, Asia-Pacific journal of clinical oncology.

Circadian variability of pharmacokinetics of cisplatin in patients with non-small-cell lung carcinoma: analysis with the NONMEM program

Jie Li, Sulan Zou, Rong Chen, 2013, Cancer Chemotherapy and Pharmacology.

Sequential administration of pemetrexed and cisplatin reprograms tumor immune microenvironment and potentiates PD-1/PD-L1 treatment in a lung cancer model

Xin Xu, Jie Li, Y. Guo, 2021, Journal of Investigative Medicine.

Nephroblastoma overexpressed gene expression and its prognostic implications of clinical outcomes in renal cell carcinoma patients.

Jie Li, Jian-qi Yu, Hongbin Shi, 2017, Cancer biomarkers : section A of Disease markers.

Epidermal growth factor receptor somatic mutation analysis in 354 Chinese patients with non-small cell lung cancer

Qiang Yu, Hongjun Gao, Jie Li, 2017, Oncology letters.

CMAR_A_287466 2033..2039

Jie Li, P. Zhao, Jie Li, 2021 .

Cisplatin-based chronotherapy for advanced non-small cell lung cancer patients: a randomized controlled study and its pharmacokinetics analysis

Mei Ji, M. Ji, Jie Li, 2015, Cancer Chemotherapy and Pharmacology.